Phase I clinical trial to assess safety and efficacy of Oraxol, a novel oral paclitaxel chemotherapy agent, in patients with previously treated metastatic breast cancer

Abstract

Oraxol, a novel oral paclitaxel chemotherapy agent, has emerged as a potential alternative for treating metastatic breast cancer (MBC). However, its safety and efficacy remain uncertain due to insufficient evidence supporting it. This open-label, single-arm, phase I trial was designed to assess the pharmacokinetics, safety, and preliminary antitumor activity of Oraxol in previously treated MBC. The primary objective was to investigate the pharmacokinetics of Oraxol, while secondary endpoints included assessing safety, tolerability, and antitumor activity. Twenty-four patients (median age, 53 years) were enrolled, and pharmacokinetic analysis showed consistent and reproducible absorption of Oraxol. Note that 96% patients experienced treatment-related adverse events (TRAEs) and no deaths attributed to TRAEs. The overall response rate was 34.8%, including 34.8% achieving partial response and 56.5% having stable disease. The median follow-up was 45.7 months, with median progression-free survival (PFS) of 3.41 months and median overall survival of 17.80 months. Notably, among patients with triple-negative breast cancer, the disease control rate was 100%, and the median PFS was 8.90 months, which notably exceeded the outcomes observed in other subtypes. Oraxol significantly alters metabolism and correlates with response and survival. In conclusion, Oraxol exhibited promising antitumor efficacy and manageable safety profiles in MBC patients.

Keywords

efficacy / metastatic breast cancer / oraxol / phase I clinical trial / safety

References

[1] KalinskyK, BarlowWE, GralowJR, et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021; 385(25): 2336-2347.

[2] SchmidP, CortesJ, DentR, et al. KEYNOTE-522 investigators. event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022; 386(6): 556-567.

[3] AgostinettoE, Gligorov J, PiccartM, Systemic therapy for early-stage breast cancer: learning from the past to build the future. Nat Rev Clin Oncol. 2022; 19(12): 763-774.

[4] SungH, FerlayJ, SiegelRL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-249.

[5] PeM, DormeL, CoensC, et al. Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review. Lancet Oncol. 2018; 19(9): e459-e469.

[6] HijaziA, Mohanna M, SabbaghS, et al. Clinico-pathologic factors and survival of patients with breast cancer diagnosed with de novo brain metastasis: a national cancer database analysis. Breast Cancer Res Treat. 2024; 206(3): 527-541.

[7] GradisharWJ, MoranMS, AbrahamJ, et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022; 20(6): 691-722.

[8] WaksAG, WinerEP, Breast cancer treatment: a review. JAMA. 2019; 321(3): 288-300.

[9] BonottoM, Gerratana L, PolettoE, et al. Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist. 2014; 19(6): 608-615.

[10] JoensuuH, Kellokumpu-Lehtinen PL, HuovinenR, et al. Adjuvant capecitabine for early breast cancer: 15-year overall survival results from a randomized trial. J Clin Oncol. 2022; 40(10): 1051-1058.

[11] MittendorfEA, ZhangH, BarriosCH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020; 396(10257): 1090-1100.

[12] SchmidP, AdamsS, RugoHS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018; 379(22): 2108-2121.

[13] KangYK, RyuMH, ParkSH, et al. Efficacy and safety findings from DREAM: a phase III study of DHP107 (Oraxol) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy. Ann Oncol. 2018; 29(5): 1220-1226.

[14] KimSB, SeoJH, AhnJH, et al. Phase II study of DHP107 (Oraxol) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study). Ther Adv Med Oncol. 2021; 13: 17588359211061989.

[15] JangY, ChungHJ, HongJW, et al. Absorption mechanism of DHP107, an Oraxol formulation that forms a hydrated lipidic sponge phase. Acta Pharmacol Sin. 2017; 38(1): 133-145.

[16] KimTE, LeeH, LimKS, et al. Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers. Br J Clin Pharmacol. 2014; 78(3): 556-564.

[17] HuangL, WangX, ZhouL, et al. Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer. Cancer Chemother Pharmacol. 2020; 85(1): 205-215.

[18] CardosoF, Paluch-Shimon S, SenkusE, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020; 31(12): 1623-1649.

[19] BursteinHJ, Somerfield MR, BartonDL, et al. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update. J Clin Oncol. 2021; 39(35): 3959-3977.

[20] GhersiD, Willson ML, ChanMM, et al. Taxane-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. 2015; 2015(6): CD003366.

[21] BishopJF, DewarJ, TonerGC, et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol. 1999; 17(8): 2355-2364.

[22] MilesD, Gligorov J, AndréF, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021; 32(8): 994-1004.

[23] CortesJ, RugoHS, CesconDW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022; 387(3): 217-226.

[24] HuppertLA, Gumusay O, IdossaD, et al. Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. CA Cancer J Clin. 2023; 73(5): 480-515.

[25] TolaneySM, Tarantino P, GrahamN, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol. 2023; 24(3): 273-285.

[26] SwainSM, MilesD, KimSB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020; 21(4): 519-530.

[27] MilesD, Ciruelos E, SchneeweissA, et al. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann Oncol. 2021; 32(10): 1245-1255.

[28] De MartinoM, Rathmell JC, GalluzziL, et al. Cancer cell metabolism and antitumour immunity. Nat Rev Immunol. 2024; 24(7): 537.

[29] SivanandS, Vander Heiden MG. Emerging roles for branched-chain amino acid metabolism in cancer. Cancer Cell. 2020; 37(2): 147-156.

[30] IcardP, Shulman S, FarhatD, et al. How the Warburg effect supports aggressiveness and drug resistance of cancer cells? Drug Resist Updat. 2018; 38: 1-11.

[31] SchwartzL, Seyfried T, AlfaroukKO, et al. Out of Warburg effect: an effective cancer treatment targeting the tumor specific metabolism and dysregulated pH. Semin Cancer Biol. 2017; 43: 134-138.

[32] MaC, ZhengK, JiangK, et al. The alternative activity of nuclear PHGDH contributes to tumour growth under nutrient stress. Nat Metab. 2021; 3(10): 1357-1371.

[33] XueC, LiG, ZhengQ, et al. Tryptophan metabolism in health and disease. Cell Metab. 2023; 35(8): 1304-1326.

[34] BaderJE, VossK, RathmellJC. Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy. Mol Cell. 2020; 78(6): 1019-1033.

[35] GradisharWJ, Tjulandin S, DavidsonN, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005; 23(31): 7794-803.

[36] RugoHS, Umanzor GA, BarriosFJ, et al. Open-label, randomized, multicenter, phase III study comparing oral paclitaxel plus encequidar versus intravenous paclitaxel in patients with metastatic breast cancer. J Clin Oncol. 2022; 20: JCO2102953.

[37] LangI, InbarMJ, KahánZ, et al. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. Eur J Cancer. 2012; 48(17): 3140-9.

[38] YuY, ChenH, OuyangW, et al. Unraveling the role of M1 macrophage and CXCL9 in predicting immune checkpoint inhibitor efficacy through multicohort analysis and single-cell RNA sequencing. MedComm, 2024; 5(3):e471.

[39] YuY, ZhangW, LiA, et al. Association of long non-coding RNA biomarkers with clinical immune subtype and prediction of immunotherapy response in patients with cancer. JAMA Network Open. 2020; 3(4): e202149.

[40] AcostaJN, Falcone GJ, RajpurkarP, et al. Multimodal biomedical AI. Nat Med. 2022; 28(9): 1773-1784.

[41] WangD, FengL, YeJ, et al. Accelerating the integration of ChatGPT and other large-scale AI models into biomedical research and healthcare. MedComm–Future Med 2023; 2:e43.

[42] CaoP-W, DengX-Y, PanY-P, et al. Early prediction of neoadjuvant chemotherapy efficacy for mass breast cancer based on dynamic contrast-enhanced magnetic resonance imaging radiomics. MedComm–Oncology 2024; 3:e84

[43] HutsonM. How AI is being used to accelerate clinical trials. Nature. 2024; 627(8003): S2-S5.

[44] AliperA, KudrinR, PolykovskiyD, et al. Prediction of clinical trials outcomes based on target choice and clinical trial design with multi-modal artificial intelligence. Clin Pharmacol Ther. 2023; 114(5): 972-980.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.